As FCA Meets 340B, Geyser Of Qui Tam Suits May Erupt
A Ninth Circuit ruling on the intersection of two of the most contentious laws in healthcare may be a combustible mix that triggers a new wave of fraud litigation.
Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal
Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, announced plans Tuesday to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.
Pacemaker Co. Seeks Clarity on Qui Tam Publicity Test
A medical device company is asking the U.S. Supreme Court to clarify the False Claims Act's public disclosure bar. To succeed, the company will have to show a true circuit split has emerged, not just differing interpretations of subjective language in the law.
As FCA Meets 340B, Geyser Of Qui Tam Suits May Erupt
A Ninth Circuit ruling on the intersection of two of the most contentious laws in healthcare may be a combustible mix that triggers a new wave of fraud litigation.
Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal
Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, announced plans Tuesday to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.
Pacemaker Co. Seeks Clarity on Qui Tam Publicity Test
A medical device company is asking the U.S. Supreme Court to clarify the False Claims Act's public disclosure bar. To succeed, the company will have to show a true circuit split has emerged, not just differing interpretations of subjective language in the law.
Expert Analysis
The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows tha... (more story)
.jpg)
The Federal Circuit's recent decision in Range of Motion v. Armaid may come to be seen as a seminal opinion for po... (more story)
The recent Delaware Supreme Court ruling in Travelers v. Blackbaud shows that cyberinsurance is moving into a seco... (more story)
Deals & Corporate Governance More
The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now ... (more story)
Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for... (more story)
A medical supply company urged the Fourth Circuit on Wednesday to revive its suit against a U.K. company over COVID-19 test kits, arguing the Chinese citizenship of one of its members doesn't destroy a North C... (more story)
Merck & Co. said Wednesday it will acquire clinical-stage oncology company Terns Pharmaceuticals Inc. for $53 per share in cash, giving the deal an equity value of $6.7 billion.
Sarepta Therapeutics Inc. wants the full Federal Circuit to rethink a decision reviving a University of Pennsylvania gene therapy patent, saying a panel got its analysis of patent eligibility wrong.
The U.S. International Trade Commission has found that an aesthetics medical device company infringed a Hydrafacial LLC skin treatment patent, but stopped short of enforcing a ban on imports.
Digital Health & Technology More
A New York federal judge on Tuesday ruled Teladoc Health Inc. cannot escape an investor suit over its declining user base and increased advertising budget, saying the departure of its former chief executive in... (more story)
A New York federal judge has upheld a $70 million compensatory damages verdict for the TriZetto Group in a long-running trade secret fight against Syntel Inc., while also cutting punitive damages to about $140... (more story)
A Delaware federal judge has affirmed a $34 million verdict against Alcon and related entities for infringing patents covering medical devices to treat glaucoma, disagreeing that Sight Sciences Inc. had failed... (more story)
A California federal judge has refused to throw out a lawsuit accusing a pair of telehealth companies of making copies of Eli Lilly's obesity and type 2 diabetes drugs but agreed to trim the case.
Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while... (more story)
A series of putative class actions resulting from a data breach at imaging practice Triad Radiology Associates PLLC hit North Carolina Business Court this week, with a couple of the cases naming hospitals that... (more story)
Policy & Compliance More
A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "co... (more story)
Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing dru... (more story)
Law360 Healthcare Authority looks at appellate arguments from compounding pharmacies alleging they were wrongly barred from making their own versions of weight loss drugs, the Federal Trade Commission's suit o... (more story)
A New Mexico medical center illegally fired an employee after failing to find her a new role that would have better accommodated her leg injury that caused lasting damage, according to a suit the U.S. Equal Em... (more story)
Major insurance companies including Aetna, Cigna, Humana and UnitedHealth must face claims they conspired to reduce reimbursements to healthcare providers, a Massachusetts federal judge ruled Monday, finding t... (more story)
A Michigan judge has upheld a state requirement that healthcare professionals undergo implicit bias training to obtain or renew their licenses, finding the mandate was within the state licensing bureau's power.